08.07.2011 • News

Slovenia's Krka Jan-June Sales Up 6% Year-On-Year

Slovenia's top pharmaceutical company Krka said on Thursday group sales rose 6% in the first half of 2011 compared with the same period last year to reach €528.8 million ($756.4 million).

In a statement after a shareholders' meeting, it said the biggest sales rise was recorded in Eastern Europe where sales jumped 12% to €134.6 million.
Krka also said it planned to list its shares on bourses outside Slovenia but gave no details.

The company also plans to continue buying its shares to up to 10% of total equity in the next three years to use them as currency for possible takeovers. At present Krka owns 5.2% of its shares.

 

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

most read